Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-28
2009-10-06
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S214020, C514S217030, C514S221000, C540S490000, C540S504000, C540S523000, C540S552000, C540S569000, C540S593000
Reexamination Certificate
active
07598237
ABSTRACT:
This invention provides progesterone receptor modulators having the structure:wherein R1to R7, X, and Q are as defined in the specification; or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 3900501 (1975-08-01), Ning et al.
patent: 4476133 (1984-10-01), Hirai et al.
patent: 4916128 (1990-04-01), Jonas et al.
patent: 5719136 (1998-02-01), Chwalisz et al.
patent: 6011029 (2000-01-01), Ding et al.
patent: 6306851 (2001-10-01), Santilli et al.
patent: 6339098 (2002-01-01), Collins et al.
patent: 6355648 (2002-03-01), Fensome et al.
patent: 6358948 (2002-03-01), Zhang et al.
patent: 6369056 (2002-04-01), Zhang et al.
patent: 6380235 (2002-04-01), Zhang et al.
patent: 6391907 (2002-05-01), Fensome et al.
patent: 6407101 (2002-06-01), Collins et al.
patent: 6417214 (2002-07-01), Ullrich et al.
patent: 6432949 (2002-08-01), Brown et al.
patent: 6514965 (2003-02-01), Tomazic et al.
patent: 0 077 983 (1983-05-01), None
patent: 0 142 361 (1985-05-01), None
patent: 0 294 647 (1988-12-01), None
patent: 0 567 026 (1993-10-01), None
patent: 08-259447 (1996-10-01), None
patent: 86/03749 (1986-07-01), None
patent: 97/48701 (1997-12-01), None
patent: 99/11635 (1999-03-01), None
patent: 99/15524 (1999-04-01), None
patent: 00/66554 (2000-11-01), None
patent: 00/66564 (2000-11-01), None
patent: 00/66570 (2000-11-01), None
patent: 00/66581 (2000-11-01), None
patent: 02/100327 (2002-12-01), None
Augustine, R. L. et al., “The Synthesis of dl-deethylibogamine,”Journal of Organic Chemsitry,Apr. 1969, 34(4), 1070-1075.
Chen, R.H.K. et al, “Synthesis and SAR of a Novel Series of Spirobenzothiazepine Derivatives with Antiprogestin Activity,” POI-37, 16thInt. Cong. Het. Chem., Montana, 1997 (Abstract).
Combs, D. W. et al., “Nonsteroidal Progesterone Receptor Ligands. 2. High-Affinity Ligands with Selectivity for Bone Cell Progesterone Receptors,”J. Med. Chem.,38, 4880-4884, 1995.
Hamann, L. G. et al., “Synthesis and and Biological Activity of Novel Nonsteroidal Progesterone Receptor Antagonists,”Ann. N.Y. Acad. Sci.,761, 383-387, 1995.
Horwitz, K. B. et al, “Progestins, Progesterone Receptors, and Breast Cancer,”Horm. Cancer,283-306, 1996, pub: Birkhaeuser, Boston, Mass., ed. Vedeckis.
Kekkonen, R. et al, “Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception,”Fertility and Sterility,60(4), 610-615, Oct. 1993.
Kettel, L. M. et al., “Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis,”Fertility and Sterility,56(3), 402-407, Sep. 1991.
Kurihara, K-I. et. al., “Synthesis of (±)-PF1092A, B, and C; New Nonsteroidal Progesterone Receptor Ligands,”J. Antibiotics,50, 360-362, Apr. 1997.
Mangelsdorf, D. J. et al., “The Nuclear Receptor Superfamily: The Second Decade,”Cell,83, 835-839, Dec. 15, 1995.
Michna, H. et al, “Differentiation Therapy with Progesterone Antagonists,”Ann. N.Y. Acad. Sci.,761, 224-247, 1995.
Murata, M. et al., “Novel Palladium(0)-Catalyzed Coupling Reaction of Dialkoxyborane with Aryl Halides: Convenient Synthetic Route to Arylboronates,”J. Org. Chem.,62, 6458-6459, 1997.
Murphy, A. A. et al, “Regression of Uterine Leiomyomata in Response to the Antiprogesterone RU 486,”J. Clin. Endo. Metab.,76(2), 513-517, 1993.
Perlman, K. L. et. al., “20-Oxopregnacalciferols: Vitamin D Compounds That Bind The Progesterone Receptor,”Tet. Letters,35(15), 2295-2298, 1994.
Robertson, D.W. et al., “Synthesis of a Tritium-Labeled Indolidan Analogue and Its Use as a Radioligand for Phosphodiesterase-Inhibitor Cardiotonic Binding Sites,”J Med Chem,1989, 32(7), 1476-1480.
Tegley, C. M. et al., “5-Benzylidene 1,2-Dihydrochromeno[3,4-ƒ]quinolines, A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists,”J. Med. Chem.41, 4354-4359, 1998.
Ulmann, A. et al., “Clinical Uses of Mifepristone (MFP),”Ann. N. Y. Acad. Sci.,261, 248-260, 1995.
Zhang, P. et al., “The reaction ofo-amino aryl carboxylic acids with Grignard reagents. The unusual effect of theN-protecting group on aryl ketone formation,”Tetrahedron Lett.(2001), 42(11), 2097-2099.
Zhi, L. et al., 5-Aryl-1,2-Dihydrochromeno[3,4-ƒ]quinolines, A Novel Class of Nonsteroidal Human Progesterone Receptor AgonistsJ. Med. Chem.,41, 291-302, 1998.
Zhi, L. et al., “Nonsteroidal Progesterone Receptor Antagonists Based on 6-Thiophenehydroquinolines,”Bioorg.&Med.Chem. Lett.10, 415-418, 2000.
Zhang et al., “7-Aryl 1,5-dihydro-benzo[e][1,4]oxazepin-2-ones and analogs as non-steroidal progesterone receptor antagonists”, Bioorg. & Med. Chem., 16(13):6589-6600 (Jul. 1, 2008).
Ramirez et al., “Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review”, Gynecological Oncology, 95(1):133-138 (Oct. 2004).
Maruo et al., “Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas”, Contraception, 75(S6):S99-103 (Mar. 21, 2007 e-publication).
Lamberts et al., “Mifepristone (U486) treatment of meningiomas”, J. Neurology and Neurosurgical psychiatry, 55(6):486-490 (Jun. 1992).
Kern et al., “1,5-Dihydro-benzo[e][1,4]oxazepin-2(1H)-ones containing a 7-(5′-cyanopyrrol-2-yl) group as nonsteroidal progesterone receptor modulators”, Bioorg. Med. Chem. Lett., 18(18):5015-5017 (Sep. 15, 2008; e-publication Aug. 9, 2008).
Kern Jeffrey Curtis
Terefenko Eugene Anthony
Wrobel Jay Edward
Zhang Puwen
Carango, Esq. Paul
Howson & Howson LLP
Kifle Bruck
Wyeth
LandOfFree
7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4111304